Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscle Invasive Bladder Cancer

Interventions

DRUG: AZD4547
DRUG: MEDI4736
DRUG: Olaparib
DRUG: AZD1775
DRUG: Vistusertib
DRUG: AZD9150
DRUG: Selumetinib

Sponsor

AstraZeneca